Atualização da Política de Não Discriminação

O Boston Medical Center Health System cumpre as leis federais de direitos civis aplicáveis ​​e não discrimina com base em idade, raça, cor, origem nacional (incluindo proficiência limitada em inglês e idioma principal), religião, cultura, deficiência física ou mental, status socioeconômico, sexo, orientação sexual e identidade e/ou expressão de gênero. O BMCHS oferece ajuda e serviços gratuitos para pessoas com deficiência e serviços linguísticos gratuitos para pessoas cujo idioma principal não é o inglês.

Para ler nossa Declaração de Não Discriminação completa, clique aqui.

The Alpha-1 Center provides comprehensive care for patients and families with alpha-1 antitrypsin deficiency (AATD), the leading genetic cause of emphysema. Our multi-disciplinary team specializes in all aspects of care for AATD, including diagnosis, genetic counseling, and treatment, combining clinical care with research to enhance outcomes.

The Pulmonology Department comprehensive diagnosis, treatment, education, and rehabilitation services for a full range of pulmonary diseases and allergy conditions.
BMC’s Gastroenterology team provides everything you need to thrive with conditions ranging from peptic ulcers, to IBD, to cancer, motility issues, and liver conditions. Our interd…
Our expert, multidisciplinary team offers a wide range of services to both treat and prevent cardiac diseases and conditions. From stents to smoking cessation, we can help you kee…

Education and Training

Pulmonary and Critical Care Fellowship

This three-year program provides training for fellows to become board-certified in both pulmonary medicine and critical care medicine. The fellowship includes clinical care at BMC and the VA Boston Healthcare system, as well as a mentored research project. An optional fourth year focused on research is also available to trainees. 

Research Overview

The Alpha-1 Center is actively involved in both laboratory-based research using patient biological samples and clinical research. Currently, we are initiating the first gene therapy trial for patients with liver complications of alpha-1 deficiency. All patients are evaluated to assess suitability for currently enrolling studies. We counsel patients about and enroll when appropriate in both observational studies and interventional clinical trials. 

Information You May Need